Corcept Therapeutics Inc CORT
Corcept Therapeutics Inc (Nasdaq: CORT) is an endocrine/women's health drug developer. Its lead program, Korlym (mifepristone), is in Phase 3 for hypercortisolism / Cushing's syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Korlym | hypercortisolism | small molecule | Approved |
| Lifyorli (relacorilant) | platinum-resistant ovarian cancer | small molecule | Approved |
| relacorilant | hypercortisolism | small molecule | Phase 3 |
| miricorilant | MASH | small molecule | Phase 2 |
| dazucorilant | ALS | small molecule | Phase 2 |
| nenocorilant | oncology | small molecule | Phase 1 |
Recent results and decisions
- Jul 29, 2026accepted Resubmitted relacorilant NDA in Cushing's syndrome carries a PDUFA date of December 17, 2026.
New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026
Filing - Jun 17, 2026submitted Corcept resubmitted the relacorilant NDA for Cushing's syndrome with additional analyses requested by FDA; six-month review expected.
Corcept expects the resubmission to receive a six-month review.
Filing - Apr 30, 2026started Initiated the Phase 2 STELLA trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer.
Initiated Phase 2 trial of relacorilant plus nab-paclitaxel in 50 patients with cervical cancer (received one or two prior lines of therapy), conducted in collaboration with ARCAGY-GINECO
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.